Guggenheim Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Market Context

EyePoint Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $14.40 with a market capitalization of $1.1B. The stock has gained 73.9% over the past 52 weeks.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for EyePoint Pharmaceuticals, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for EyePoint Pharmaceuticals, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 24, 2026	Guggenheim	Buy	N/A
May 07, 2026	RBC Capital	Outperform	N/A
Mar 09, 2026	Citigroup	Buy	N/A
Mar 05, 2026	HC Wainwright & Co.	Buy	N/A
Mar 04, 2026	Chardan Capital	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View EYPT Stock Page